GC Cell to develop new lymphoma drug with fewer side effects

[Source: GC Cell]

GC Cell has added an NK cell therapy to its pipeline with a goal to develop a new lymphoma drug with reduced side effects. The candidate codenamed CT205A specifically binds to CD5 protein known to be involved in the development of the blood cancer, the company said on Tuesday.

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]